- Home
- PMAX vs GLTO Comparison
PMAX vs GLTO Comparison
Compare PMAX & GLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMAX
- GLTO
- Stock Information
- Founded
- PMAX 2019
- GLTO 2011
- Country
- PMAX Hong Kong
- GLTO Denmark
- Employees
- PMAX N/A
- GLTO N/A
- Industry
- PMAX
- GLTO Biotechnology: Pharmaceutical Preparations
- Sector
- PMAX
- GLTO Health Care
- Exchange
- PMAX Nasdaq
- GLTO Nasdaq
- Market Cap
- PMAX 6.6M
- GLTO 6.5M
- IPO Year
- PMAX 2024
- GLTO 2020
- Fundamental
- Price
- PMAX $0.45
- GLTO $3.23
- Analyst Decision
- PMAX
- GLTO Buy
- Analyst Count
- PMAX 0
- GLTO 1
- Target Price
- PMAX N/A
- GLTO $10.00
- AVG Volume (30 Days)
- PMAX 820.9K
- GLTO 719.8K
- Earning Date
- PMAX 04-15-2025
- GLTO 03-19-2025
- Dividend Yield
- PMAX N/A
- GLTO N/A
- EPS Growth
- PMAX N/A
- GLTO N/A
- EPS
- PMAX 0.04
- GLTO N/A
- Revenue
- PMAX $5,970,263.00
- GLTO N/A
- Revenue This Year
- PMAX N/A
- GLTO N/A
- Revenue Next Year
- PMAX N/A
- GLTO N/A
- P/E Ratio
- PMAX $8.96
- GLTO N/A
- Revenue Growth
- PMAX 30.05
- GLTO N/A
- 52 Week Low
- PMAX $0.28
- GLTO $2.79
- 52 Week High
- PMAX $4.70
- GLTO $19.75
- Technical
- Relative Strength Index (RSI)
- PMAX N/A
- GLTO 40.83
- Support Level
- PMAX N/A
- GLTO $2.79
- Resistance Level
- PMAX N/A
- GLTO $7.30
- Average True Range (ATR)
- PMAX 0.00
- GLTO 0.78
- MACD
- PMAX 0.00
- GLTO -0.17
- Stochastic Oscillator
- PMAX 0.00
- GLTO 9.76
About PMAX Powell Max Limited Class A Ordinary Shares
Powell Max Ltd is an financial communications services provider. Its financial communications services cover a full range of financial printing, corporate reporting, communications and language support services from inception to completion, including typesetting, proofreading, translation, design, printing, electronic reporting, newspaper placement and distribution. It operates in a single business segment which is the provision of corporate financial communications and financial printing services. Key revenue is derived from Hong Kong.
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.